A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer

A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer

After androgen deprivation therapy, a significant number of prostate cancer cases progress with a therapy-resistant neuroendocrine phenotype (NEPC). This represents a challenge for diagnosis and treatment. Based on our previously reported design of theranostic small-molecule prodrug conjugates (T-SM...

Full description

Bibliographic Details
Main Authors: Paulina Gonzalez, Sashi Debnath, Yu-An Chen, Elizabeth Hernandez, Preeti Jha, Marianna Dakanali, Jer-Tsong Hsieh, Xiankai Sun
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Pharmaceutics
Subjects:
prodrug conjugate
drug delivery
controlled drug release
theranostics
positron emission tomography (PET)
targeted therapy
Online Access:https://www.mdpi.com/1999-4923/15/2/481

Internet

https://www.mdpi.com/1999-4923/15/2/481

Similar Items